Publikation

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

Wissenschaftlicher Artikel/Review - 06.03.2000

Bereiche
PubMed

Zitation
Ludewig B, Ochsenbein A, Odermatt B, Paulin D, Hengartner H, Zinkernagel R. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. The Journal of experimental medicine 2000; 191:795-804.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
The Journal of experimental medicine 2000; 191
Veröffentlichungsdatum
06.03.2000
ISSN (Druck)
0022-1007
Seiten
795-804
Kurzbeschreibung/Zielsetzung

Vaccination with dendritic cells (DCs) presenting tumor antigens induces primary immune response or amplifies existing cytotoxic antitumor T cell responses. This study documents that antitumor treatment with DCs may cause severe autoimmune disease when the tumor antigens are not tumor-specific but are also expressed in peripheral nonlymphoid organs. Growing tumors with such shared tumor antigens that were, at least initially, strictly located outside of secondary lymphoid organs were successfully controlled by specific DC vaccination. However, antitumor treatment was accompanied by fatal autoimmune disease, i.e., autoimmune diabetes in transgenic mice expressing the tumor antigen also in pancreatic beta islet cells or by severe arteritis, myocarditis, and eventually dilated cardiomyopathy when arterial smooth muscle cells and cardiomyocytes expressed the transgenic tumor antigen. These results reveal the delicate balance between tumor immunity and autoimmunity and therefore point out important limitations for the use of not strictly tumor-specific antigens in antitumor vaccination with DCs.